Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22356081 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL10012464 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL2462169 | 0.79 | — | — | |
| SCHEMBL12986610 | 0.79 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL28672884 | 0.79 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL24654642 | 0.78 | SMN1; SMN2 (0.38) | SMN1; SMN2CA14CA12 | |
| SCHEMBL5964949 | 0.78 | — | — | |
| SCHEMBL10011696 | 0.78 | CA1 (0.37) | SMN1; SMN2CA14CA1CA2 | |
| SCHEMBL26298907 | 0.77 | KDM4E (0.38) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL10011693 | 0.76 | TSHR (0.40) | SMN1; SMN2CA14CA12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | SHIONOGI & CO., LTD. (JP) | 2021-06-22 | — | — | US | disclosed |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | SHIONOGI & CO., LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | RNASEH1, RNASEL, RNPEP | SMN1; SMN2 4589/4885CA14 43/4885CA12 154/4885 |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | RNASEH1, RNPEP, RNASEL | SMN1; SMN2 4672/4885CA14 33/4885CA12 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.